Table 6.

Outcomes of patients with uterine cancer detected on final pathology

Patient Age (years)	Final Pathology	Subsequent procedure	Follow-up (months)
40	Grade 3 endometrioid adenocarcinoma invading 50% of myometrium with lymphvascular space invasion	None	81.7
44	Grade 1 villoglandular endometrioid adenocarcinoma with no myometrial invasion	Exploratory laparotomy, trachelectomy, bilateral salpingo-oophorectomy, washings, staging (all specimens negative for disease)	93.7
49	Endometrial stromal sarcoma	Exploratory laparotomy, trachelectomy, left salpingo-oophorectomy, optimal tumor reductive surgery for multiple peritoneal nodules; received 5 years of letrozole	90.4
60	Leiomyosarcoma involving pelvic sidewall with all staging biopsies and lymph nodes negative	None (converted to open procedure); received 6 courses of adjuvant adriamycin and dacarbazine with complete response. Recurred 42 months after surgery in pelvis, psoas, liver, and lungs; progressed on gemcitabine and docetaxel; died of disease 54.3 months after diagnosis	57.8